CD8A and cancer: Recent findings have further complicated the role of ferroptosis in cancer therapy, suggesting that traditional ferroptosis inducers can not only kill cancer cells but may also impair antitumor immune cells, such as CD8+ T cells[18,19], dendritic cells[20], and natural killer cells[21], thereby weakening the overall antitumor immune response.